StreetAlpha.app
Home › Stocks › UNCY

Unicycive Therapeutics, Inc. (UNCY)

Healthcare
$3.70
▲ +0.00%
LAST CLOSE · NOV 17

Unicycive is a biotechnology company developing drug candidates for kidney disease, including treatments for dialysis patients. It last closed at $3.70 on Nov 17, up 0.00% on the day.

AI Auto Pilots
Is UNCY in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$36.2M
EPS (diluted)
−$1.64
Free cash flow
−$29.4M
Valuation
Market cap
$108.0M
29.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$42.0M
At Sep 30
Shareholder equity
$52.6M
Shares outstanding
29.2M
At Nov 16
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$10.0M−$10.0MFY2021FY2022: −$18.1M−$18.1MFY2022FY2023: −$30.5M−$30.5MFY2023FY2024: −$36.7M−$36.7MFY2024FY2025: −$26.6M−$26.6MFY2025

From UNCY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated UNCY in the past 90 days, not enough for a consensus
Average 12-month target
$13.00
▲ 251.4% upside

Based on 1 analyst who set a price target on UNCY in the past 90 days. The average target is $13.00, with a high of $13.00 and a low of $13.00, compared with the last close of $3.70.

Low $13.00Avg $13.00High $13.00
Blue marker: last close $3.70
Highest target$13.00
Average target$13.00
Lowest target$13.00
Latest rating changes
HC Wainwright & Co.Target lowered
Sep 29Buy$15 → $13
GuggenheimMaintained
Aug 13Buy$25
B. Riley SecuritiesTarget lowered
Aug 13Buy$22 → $20
BenchmarkTarget lowered
Jul 1Buy$18 → $13
Noble Capital MarketsMaintained
Jul 1Buy$50
DateFirmActionRatingPrice target
Sep 29HC Wainwright & Co.Target loweredBuy$15 → $13
Aug 13GuggenheimMaintainedBuy$25
Aug 13B. Riley SecuritiesTarget loweredBuy$22 → $20
Jul 1BenchmarkTarget loweredBuy$18 → $13
Jul 1Noble Capital MarketsMaintainedBuy$50
Loading…

Technical Analysis

UNCY · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 60% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the 20 day average at $3.69, and the nearest resistance the Pivot R1 at $3.78.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$8.7452 week high+136.2%
$5.92200 day average+60.0%
$4.73100 day average+27.8%
$4.1450 day average+11.9%
$3.85Swing high (Nov 11)+4.1%
$3.78Pivot R1+2.2%
$3.70Last close
$3.6920 day average−0.3%
$3.69Pivot−0.3%
$3.61Pivot S1−2.4%
$3.48Swing low (Oct 27)−5.9%
$3.3352 week low−10.0%
Indicators
RSI (14)46.61Middle of its rangeNeutral
MACD-0.12Above its signal lineBullish
Stochastic53.3Middle of its rangeNeutral
ADX (14)26.0Trending down
Williams %R-38.3Oversold below −80, overbought above −20Neutral
CCI (20)1.3Oversold below −100, overbought above 100Neutral
Rate of change+3.1%Change over 10 sessionsBullish
ATR (14)$0.23Typical daily range, 6.1% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for UNCY

What happened before

See how UNCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow UNCY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How UNCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in UNCY in the last 90 days.

Loading…

See today’s whale options flow across the market →

UNCY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲63 buying vs 29 selling
  • ▼Held by funds -5.7 pts
  • ▲Funds holding +15
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9580+18.8%
In funds' top 1010–
Held by funds39.1%44.8%−5.7 pts
New / increased26 / 3736 / 23+6.8%
Reduced / sold out17 / 1211 / 7+61.1%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See UNCY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UNCY is in one of them and how their past UNCY trades turned out.

UNCY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered UNCY in an article yet. Here's the latest on the wider market.

About Unicycive Therapeutics

Unicycive is a biotechnology company based in Mountain View, California, that is developing drugs for kidney disease. Its lead candidate, oxylanthanum carbonate, is a tablet meant to control high phosphorus levels in patients on dialysis, and it is designed to be swallowed whole rather than chewed. Its second candidate, UNI-494, is in development for acute kidney injury, a condition for which no FDA approved medicines currently exist. The company plans to seek approvals in the United States and to partner with other drugmakers in other markets.

Headquarters
Mountain View, CA